Public Health Impact After the Introduction of PsA-TT: The First 4 Years

Abstract

Background. During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010–2011 and its rollout from 2011 to 2013, >150 million eligible people, representing 12 hyperendemic meningitis countries, have been vaccinated.Methods. The new vaccine effectiveness evaluation framework was established by the World Health Organization and partners. Meningitis case-based surveillance was strengthened in PsA-TT first-introducer countries, and several evaluation studies were conducted to estimate the vaccination coverage and to measure the impact of vaccine introduction on meningococcal carriage and disease incidence.Results. PsA-TT implementation achieved high vaccination coverage, and results from studies conducted showed significant decrease of disease incidence as well as significant reduction of oropharyngeal carriage of group A meningococci in vaccinated and unvaccinated individuals, demonstrating the vaccine's ability to generate herd protection and prevent group A epidemics.Conclusions. Lessons learned from this experience provide useful insights in how to guide and better prepare for future new vaccine introductions in resource-limited settings.

Impact of introduction of rapid diagnostic tests for malaria on antibiotic prescribing: analysis of observational and randomised studies in public and private healthcare settings

“…Widespread childhood vaccination for pneumococcus, meningococcus, and Haemophilus influenzae type B, and the resulting reduction in bacteraemia and bacterial infection, have further reduced the risk that non-specific, non-severe febrile illness is caused by a potentially serious bacterial pathogen in many African and Asian countries. [58][59][60] Even when treatment with antibiotics is warranted, patients might not receive the most appropriate antibiotic for their illness, particularly in settings with inadequate healthcare infrastructure. 20 In the studies we analysed, choice of antibacterial was inevitably untargeted as health workers in these settings do not have access to facilities to confirm diagnoses and identify pathogens nor to epidemiological data to help guide antibiotic choices-a health system weakness that is unfortunately typical across most malaria endemic areas.…”

Bacterial agents causing meningitis during 2013–2014 in Turkey: A multi-center hospital-based prospective surveillance study

“…[16][17][18][19] Before the widespread use of a conjugate meningoccoccal group A vaccine, seasonal meningitis epidemics caused by group A caused high toll of morbidity and mortality in the African meningitis belt countries. 20 Serogroup W-135 causes outbreaks in some parts of the world, primarily in Saudi Arabia and Africa. 14,15,21 Since the 1990s, isolates of serogroup X have been reported in several countries within the meningitis belt.…”

Neisseria: recent advances and future challenges

“…The Meningitis Research Foundation (MRF) Genome Library was the first nationwide repository of genome sequence data of any major bacterial pathogen (Hill et al 2015), and provides sequence data on all meningococcal disease isolates from UK. It is evident that MenAfrivac has had an enormous impact on reducing the burden of meningococcal disease in Sub-Saharan Africa caused by serogroup A strains (Diomandé et al 2015). Vaccines against serogroup B strains of N. meningitidis, once the bane of vaccine development due to their nonimmunogenic capsule, have recently become available.…”